[go: up one dir, main page]

CL2003002683A1 - Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos, - Google Patents

Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,

Info

Publication number
CL2003002683A1
CL2003002683A1 CL200302683A CL2003002683A CL2003002683A1 CL 2003002683 A1 CL2003002683 A1 CL 2003002683A1 CL 200302683 A CL200302683 A CL 200302683A CL 2003002683 A CL2003002683 A CL 2003002683A CL 2003002683 A1 CL2003002683 A1 CL 2003002683A1
Authority
CL
Chile
Prior art keywords
compounds
oxoetoxi
etoxipropanoic
enantiomers
phenyl
Prior art date
Application number
CL200302683A
Other languages
English (en)
Inventor
Eva-Lotte Lindstedt Alstermark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2003002683A1 publication Critical patent/CL2003002683A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200302683A 2002-12-21 2003-12-18 Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos, CL2003002683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229931.1A GB0229931D0 (en) 2002-12-21 2002-12-21 Therapeutic agents

Publications (1)

Publication Number Publication Date
CL2003002683A1 true CL2003002683A1 (es) 2005-04-08

Family

ID=9950253

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302683A CL2003002683A1 (es) 2002-12-21 2003-12-18 Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,

Country Status (21)

Country Link
US (1) US7462644B2 (es)
EP (1) EP1572626A1 (es)
JP (2) JP3786945B2 (es)
KR (1) KR20050089065A (es)
CN (1) CN1308291C (es)
AR (1) AR042632A1 (es)
AU (1) AU2003290309B2 (es)
BR (1) BR0317458A (es)
CA (1) CA2508851A1 (es)
CL (1) CL2003002683A1 (es)
CO (1) CO5580820A2 (es)
GB (1) GB0229931D0 (es)
IS (1) IS7946A (es)
MX (1) MXPA05006812A (es)
NO (1) NO20052914L (es)
PL (1) PL377144A1 (es)
RU (1) RU2005117792A (es)
TW (1) TW200508180A (es)
UA (1) UA80729C2 (es)
WO (1) WO2004056748A1 (es)
ZA (1) ZA200504730B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
KR20040093692A (ko) 2002-03-13 2004-11-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
CN100503599C (zh) 2002-03-13 2009-06-24 詹森药业有限公司 作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003218736B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
TWI282784B (en) 2002-06-20 2007-06-21 Astrazeneca Ab Therapeutic agents
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
ATE552246T1 (de) 2005-05-31 2012-04-15 Pfizer Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
ES2376121T3 (es) 2006-01-19 2012-03-09 Janssen Pharmaceutica, N.V. Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
CA2633100C (en) 2006-01-19 2014-12-09 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
HRP20090459T1 (hr) 2006-01-19 2009-09-30 Janssen Pharmaceutica N.V. Aminofenil derivati kao novi inhibitori histonskih deacetilaza
EP1979327A1 (en) 2006-01-19 2008-10-15 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
BRPI0823522A2 (pt) 2007-10-05 2014-01-07 Genzyme Corp Uso de um composto derivado de ceramida
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
AU2011326871B2 (en) 2010-11-04 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
DK3921028T3 (da) 2019-02-06 2023-01-23 Albireo Ab Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP7695242B2 (ja) 2019-12-04 2025-06-18 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7748451B2 (ja) 2020-08-03 2025-10-02 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (es)
BE489216A (es) 1948-06-05 1900-01-01
US2928840A (en) 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
WO1999011606A2 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
AU738134B2 (en) * 1997-10-02 2001-09-06 Sankyo Company Limited Amidocarboxylic acid derivatives
AU1457299A (en) 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
KR20020060067A (ko) 1999-04-06 2002-07-16 가와무라 요시부미 α-치환 카르복실산 유도체
AU3670900A (en) 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
JP2000351777A (ja) * 1999-04-08 2000-12-19 Sankyo Co Ltd 置換縮合イミダゾール誘導体
US6620929B1 (en) 1999-04-14 2003-09-16 University Of British Columbia 1,3-Dipolar cycloadditions to polypyrrolic macrocycles
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
CN1331862C (zh) 1999-04-28 2007-08-15 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
WO2002044127A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitué
WO2002044130A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitués
CA2438551A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
WO2002083616A1 (en) 2001-04-10 2002-10-24 Sankyo Company, Limited α-SUBSTITUTED φ-ARYLFATTY ACID DERIVATIVE
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
RU2005117792A (ru) 2006-01-27
CN1753862A (zh) 2006-03-29
AR042632A1 (es) 2005-06-29
CN1308291C (zh) 2007-04-04
CO5580820A2 (es) 2005-11-30
PL377144A1 (pl) 2006-01-23
NO20052914D0 (no) 2005-06-15
WO2004056748A1 (en) 2004-07-08
JP2006511572A (ja) 2006-04-06
NO20052914L (no) 2005-07-19
EP1572626A1 (en) 2005-09-14
MXPA05006812A (es) 2005-09-08
KR20050089065A (ko) 2005-09-07
GB0229931D0 (en) 2003-01-29
AU2003290309B2 (en) 2007-01-18
ZA200504730B (en) 2006-09-27
JP3786945B2 (ja) 2006-06-21
TW200508180A (en) 2005-03-01
CA2508851A1 (en) 2004-07-08
US20050131068A1 (en) 2005-06-16
BR0317458A (pt) 2005-11-16
JP2006045240A (ja) 2006-02-16
IS7946A (is) 2005-07-19
AU2003290309A1 (en) 2004-07-14
US7462644B2 (en) 2008-12-09
UA80729C2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
BRPI0413490A (pt) novos compostos
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
NL300933I2 (nl) Letermovir
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
TW200612892A (en) Novel compounds
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
UY26130A1 (es) Compuestos para tratar la obesidad
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
TW200621690A (en) Novel compounds
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
CL2004000806A1 (es) Compuestos derivados de quinazolinas, inhibidores de quinasa p38, composicion farmaceutica, procedimiento de preparacion, utiles para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon, sepsis, infarto al miocardio y otras.
BRPI0414868A (pt) composições e métodos compreendendo compostos relacionados com prostaglandina e peptìdios da famìlia do fator trifoliado para o tratamento de glaucoma com hiperemia reduzida
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação